Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | TLR2 | O60603 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL225095 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL40466 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL18383707 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL722740 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL22771162 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL23274175 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL14706366 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL16283397 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL15444409 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL31536455 | 0.98 | MEN1 (0.44) | TSHRMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115353468-B | Preparation method of p-toluenesulfonyloxy substituted oligoethylene glycol tert-butyl propionate | 安阳工学院 | 2023-06-30 | — | — | CN | claimed |
| CN-115353468-A | Preparation method of p-toluenesulfonyloxy substituted tert-butyl oligo (ethylene glycol) propionate | 安阳工学院 | 2022-11-18 | — | — | CN | claimed |
| CN-107235848-B | A kind of preparation method of amino-polyethyleneglycols propionic acid | 湖南华腾制药有限公司 | 2019-06-18 | — | — | CN | claimed |
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | NURIX THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4660303-A2 | PCSK9 ANTAGONIST COMPOUNDS | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | CALICO LIFE SCIENCES LLC | 2025-10-02 | — | — | US | disclosed |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2025-07-24 | — | — | US | disclosed |
| EP-3810626-B1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-06-26 | — | — | US | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250163066-A1 | PROTACs of MALT1 | TEGID THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-7691962-B2 | Chemical linkers and conjugates thereof | MEDAREX, INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20090264600-A1 | Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264600-A1 | Method for Preparing Water-Soluble Polymer Derivatives Bearing a Terminal Carboxylic Acid | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-10-22 | — | — | US | disclosed |
| US-7569214-B2 | Hydrolysing water-soluble polyoxyethylene glycol segment having alkoxide ion or thiolate ion with ortho ester comprised of suitable leaving group (methanesulfonate) | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569214-B2 | Hydrolysing water-soluble polyoxyethylene glycol segment having alkoxide ion or thiolate ion with ortho ester comprised of suitable leaving group (methanesulfonate) | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | MEDAREX, INC. (US) | 2008-11-13 | — | — | US | disclosed |
| EP-1537163-B1 | METHOD FOR PREPARING WATER-SOLUBLE POLYMER DERIVATIVES BEARING A TERMINAL CARBOXYLIC ACID | NEKTAR THERAPEUTICS AL CORP (US) | 2008-10-29 | — | — | EP | disclosed |
| US-7199100-B2 | Oligopeptides; antitumor agents, antiinflammatory agents, antiischemic agents, vision defects | COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528814-B2 | Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof | IRAK1, IRAK2, IRAK3 | TSHR 1625/4885MAPK1 347/4885MEN1 3809/4885 |
| US-20250163066-A1 | PROTACs of MALT1 | MALT1, BCL3, BCL9 | TSHR 4573/4885MAPK1 1548/4885MEN1 656/4885 |
| US-20250302815-A1 | PROTEIN TYROSINE PHOSPHATASE TARGETING LIGANDS | PTPN1, PTPN2, PTPN18 | TSHR 538/4885MAPK1 423/4885MEN1 3882/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | TSHR 1939/4885MAPK1 4210/4885MEN1 2815/4885 |
| US-20080279868-A1 | Antibody-Drug Conjugates and Methods of Use | CD47, ANTXR2, CD2BP2 | TSHR 2341/4885MAPK1 4518/4885MEN1 2114/4885 |
| US-20250235543-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, TP53BP1 | TSHR 3311/4885MAPK1 2708/4885MEN1 2854/4885 |
| US-20250206781-A1 | PCSK9 ANTAGONIST COMPOUNDS | PCSK9, PCSK7, PCSK6 | TSHR 531/4885MAPK1 572/4885MEN1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.